- Home
- SILC vs CGEN Comparison
SILC vs CGEN Comparison
Compare SILC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | CGEN |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 143.1M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SILC | CGEN |
|---|---|---|
| Price | $14.45 | $1.58 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 426.3K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,509,000.00 | $6,903,000.00 |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $14.36 | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.44 | $1.13 |
| 52 Week High | $19.37 | $2.66 |
Technical Indicators
Market Signals| Indicator | SILC | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 53.21 |
| Support Level | $13.54 | $1.43 |
| Resistance Level | $14.20 | $1.55 |
| Average True Range (ATR) | 0.44 | 0.07 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 69.73 | 63.83 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.